Matt Miksic
Stock Analyst at Barclays
(3.79)
# 714
Out of 5,149 analysts
335
Total ratings
57.47%
Success rate
5.86%
Average return
Main Sectors:
Stocks Rated by Matt Miksic
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LIVN LivaNova | Maintains: Equal-Weight | $67 → $73 | $68.43 | +6.68% | 10 | Feb 27, 2026 | |
| ALC Alcon | Maintains: Equal-Weight | $86 → $90 | $83.08 | +8.33% | 11 | Feb 26, 2026 | |
| GMED Globus Medical | Maintains: Overweight | $118 → $123 | $91.70 | +34.13% | 17 | Feb 25, 2026 | |
| BLCO Bausch + Lomb | Maintains: Equal-Weight | $17 → $20 | $17.98 | +11.23% | 7 | Feb 19, 2026 | |
| MDT Medtronic | Maintains: Overweight | $116 → $118 | $96.71 | +22.01% | 25 | Feb 18, 2026 | |
| DXCM DexCom | Maintains: Underweight | $71 → $72 | $73.08 | -1.48% | 10 | Feb 13, 2026 | |
| BAX Baxter International | Maintains: Overweight | $30 → $25 | $19.03 | +31.37% | 24 | Feb 13, 2026 | |
| ZBH Zimmer Biomet Holdings | Maintains: Underweight | $104 → $100 | $97.97 | +2.07% | 10 | Feb 12, 2026 | |
| BDX Becton, Dickinson and Company | Reinstates: Overweight | $202 | $174.21 | +15.95% | 2 | Feb 11, 2026 | |
| GEHC GE HealthCare Technologies | Maintains: Equal-Weight | $86 → $87 | $78.13 | +11.35% | 2 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $136 → $124 | $73.85 | +67.91% | 20 | Feb 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $169 → $142 | $113.61 | +24.99% | 32 | Feb 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $97 → $98 | $83.37 | +17.55% | 2 | Jan 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $686 → $712 | $497.42 | +43.14% | 9 | Jan 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $103 → $104 | $85.28 | +21.95% | 32 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $316 → $274 | $241.84 | +13.30% | 12 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $12 | $4.36 | +175.23% | 4 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $27 | $13.02 | +107.37% | 5 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $197 → $217 | $246.75 | -12.06% | 15 | Dec 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $51 → $55 | $23.74 | +131.68% | 8 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1.5 → $31 | $6.83 | +354.21% | 2 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $443 → $453 | $384.59 | +17.79% | 24 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3.5 | $1.07 | +227.10% | 1 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $21 | $13.60 | +54.41% | 14 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $6.44 | +241.61% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $100 | $80.21 | +24.67% | 8 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $722 → $418 | $182.64 | +128.87% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $15.70 | +78.34% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $67 | $13.30 | +403.76% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $480 | $1.92 | +24,900.00% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $87 | $10.56 | +723.86% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $2.87 | +771.08% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $24 | $10.07 | +138.33% | 1 | Oct 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $9 | $4.76 | +89.08% | 1 | Dec 12, 2016 |
LivaNova
Feb 27, 2026
Maintains: Equal-Weight
Price Target: $67 → $73
Current: $68.43
Upside: +6.68%
Alcon
Feb 26, 2026
Maintains: Equal-Weight
Price Target: $86 → $90
Current: $83.08
Upside: +8.33%
Globus Medical
Feb 25, 2026
Maintains: Overweight
Price Target: $118 → $123
Current: $91.70
Upside: +34.13%
Bausch + Lomb
Feb 19, 2026
Maintains: Equal-Weight
Price Target: $17 → $20
Current: $17.98
Upside: +11.23%
Medtronic
Feb 18, 2026
Maintains: Overweight
Price Target: $116 → $118
Current: $96.71
Upside: +22.01%
DexCom
Feb 13, 2026
Maintains: Underweight
Price Target: $71 → $72
Current: $73.08
Upside: -1.48%
Baxter International
Feb 13, 2026
Maintains: Overweight
Price Target: $30 → $25
Current: $19.03
Upside: +31.37%
Zimmer Biomet Holdings
Feb 12, 2026
Maintains: Underweight
Price Target: $104 → $100
Current: $97.97
Upside: +2.07%
Becton, Dickinson and Company
Feb 11, 2026
Reinstates: Overweight
Price Target: $202
Current: $174.21
Upside: +15.95%
GE HealthCare Technologies
Feb 6, 2026
Maintains: Equal-Weight
Price Target: $86 → $87
Current: $78.13
Upside: +11.35%
Feb 3, 2026
Maintains: Overweight
Price Target: $136 → $124
Current: $73.85
Upside: +67.91%
Feb 2, 2026
Maintains: Overweight
Price Target: $169 → $142
Current: $113.61
Upside: +24.99%
Jan 26, 2026
Maintains: Overweight
Price Target: $97 → $98
Current: $83.37
Upside: +17.55%
Jan 26, 2026
Maintains: Overweight
Price Target: $686 → $712
Current: $497.42
Upside: +43.14%
Jan 12, 2026
Maintains: Overweight
Price Target: $103 → $104
Current: $85.28
Upside: +21.95%
Jan 12, 2026
Downgrades: Underweight
Price Target: $316 → $274
Current: $241.84
Upside: +13.30%
Jan 9, 2026
Maintains: Overweight
Price Target: $11 → $12
Current: $4.36
Upside: +175.23%
Jan 7, 2026
Maintains: Overweight
Price Target: $23 → $27
Current: $13.02
Upside: +107.37%
Dec 30, 2025
Maintains: Equal-Weight
Price Target: $197 → $217
Current: $246.75
Upside: -12.06%
Nov 10, 2025
Maintains: Overweight
Price Target: $51 → $55
Current: $23.74
Upside: +131.68%
Nov 5, 2025
Maintains: Overweight
Price Target: $1.5 → $31
Current: $6.83
Upside: +354.21%
Oct 22, 2025
Maintains: Overweight
Price Target: $443 → $453
Current: $384.59
Upside: +17.79%
Aug 27, 2025
Initiates: Overweight
Price Target: $3.5
Current: $1.07
Upside: +227.10%
Jul 30, 2025
Maintains: Overweight
Price Target: $24 → $21
Current: $13.60
Upside: +54.41%
Jan 7, 2025
Initiates: Overweight
Price Target: $22
Current: $6.44
Upside: +241.61%
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $80.21
Upside: +24.67%
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $182.64
Upside: +128.87%
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $15.70
Upside: +78.34%
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $13.30
Upside: +403.76%
Jan 7, 2022
Initiates: Outperform
Price Target: $480
Current: $1.92
Upside: +24,900.00%
Nov 3, 2021
Maintains: Outperform
Price Target: $84 → $87
Current: $10.56
Upside: +723.86%
Aug 10, 2021
Maintains: Outperform
Price Target: $24 → $25
Current: $2.87
Upside: +771.08%
Oct 10, 2017
Maintains: Buy
Price Target: $26 → $24
Current: $10.07
Upside: +138.33%
Dec 12, 2016
Initiates: Sell
Price Target: $9
Current: $4.76
Upside: +89.08%